← All trials
NCT06616025
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2025
- Primary completion
- Jan 31, 2027
- Completion date
- Mar 31, 2027
- First posted
- Sep 27, 2024
- Last posted
- Oct 1, 2024
- Enrollment
- 98
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Neuraptive Therapeutics Inc.Lead sponsor
- Neuraptive Therapeutics Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.